AstraZeneca allocates $570M for Canadian expansion, creating 700+ jobs and boosting R&D, solidifying Canada as a global life sciences innovation hub.
AI memory chips are driving innovation with advancements in HBM technology, energy efficiency, and scalability, shaping AI applications and market growth by 2025.
Discover how mergers and acquisitions in biotech and pharma are reshaping 2025, driven by innovation, patent cliffs, and regulatory shifts under new policies.
Trump unveils $500 billion AI initiative with OpenAI, Oracle, and SoftBank, aiming to boost U.S. tech leadership with advanced AI infrastructure and innovation.
What Trump's CMS can and can't change in 2025: Medicare drug price negotiations aim to lower costs, but challenges with innovation and industry pushback remain.
Roche executive advocates balanced approach amid GLP-1 weight loss trend as demand for these transformative drugs reshapes obesity and diabetes care in 2025.
Indonesia targets 200m free medical checkups improving human capital to support Prabowo's 8% growth goal by boosting workforce productivity and reducing health costs.
Moderna lowers 2025 revenue estimate to $1.5-$2.5B due to declining COVID vaccine demand, slower RSV vaccine adoption, and $1B in planned cost cuts.
Gilead roars into JPM25 with a $1.7B deal, expanding into inflammation via STAT6 inhibitors, diversifying its portfolio, and redefining treatment landscapes.
Nvidia’s tiny $3,000 AI supercomputer redefines AI development in 2025, offering 1 petaflop power, affordability, and local model training for developers.